152030-49-4

Basic information

• Product Name: 1H-Imidazole-4-propanol, 1-(triphenylmethyl)-
• Synonyms: 1H-Imidazole-4-propanol, 1-(triphenylmethyl)-
• CAS NO: 152030-49-4
• Molecular Formula: C₂₅H₂₄N₂O
• Molecular Weight: 368.47086
• Mol File: 152030-49-4.mol
• Article Data: 15

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Imidazole-4-propanol, 1-(triphenylmethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Imidazole-4-propanol, 1-(triphenylmethyl)-(152030-49-4)
• EPA Substance Registry System: 1H-Imidazole-4-propanol, 1-(triphenylmethyl)-(152030-49-4)

Safety Data

• Hazardous Substances Data: 152030-49-4(Hazardous Substances Data)

Upstream product

• 49549-75-9 4-(3-hydroxypropyl)-1H-imidazole 
• 76-83-5 trityl chloride 
• 110-87-2 3,4-dihydro-2H-pyran 
• 1074-59-5 3-(imidazol-4-yl)propionic acid 
• 3465-72-3 urocanic Acid 
• 52237-38-4 ethyl 3-(imidazol-4'-yl)-propanoate 
• 75-04-7 ethylamine 
• 54260-89-8 trans-4-imidazoleacrylic acid methyl ester hydrochloride 
• 102676-60-8 3-(1-triphenylmethyl-1H-imidazol-4-yl)propanoic acid methyl ester 
• 104-98-3 urocanic acid 
• 53958-94-4 3-(1H-imidazol-4-yl)propionic acid methyl ester hydrochloride 
• 31434-93-2 methyl 3-(4-imidazolyl)propionate 
• 5324-21-0 3-bromo-2-methoxy-tetrahydropyran 
• 3465-72-3 (E)-3-(1H-imidazol-4-yl)propenoic acid 

Downstream Products

• 152030-50-7 4-[3-(1-Trityl-1H-imidazol-4-yl)-propoxy]-benzonitrile 
• 183155-62-6 3-<1-(triphenylmethyl)imidazol-4(5)-yl>propyl benzyl ether 
• 183155-66-0 3-<1-(triphenylmethyl)imidazol-4(5)-yl>propyl 4-bromobenzyl ether 
• 102676-61-9 3-(1-triphenylmethyl-4-imidazolyl)propionaldehyde 
• 183155-63-7 3-(1-triphenylmethyl-1H-imidazol-4-yl)propyl 4-fluorobenzyl ether 
• 315674-93-2 cyclopropyl-{4-[3-(1-trityl-1H-imidazol-4-yl)-propoxy]-phenyl}-methanone 

Relevant articles and documents

3,4,5-TRISUBSTITUTED-1,2,4-TRIAZOLES AND 3,4,5-TRISUBSTITUTED-3-THIO-1,2,4-TRIAZOLES AND USES THEREOF

The present disclosure describes novel compounds that are somatostatin receptor type 4 agonists.

DOUBLE-ACYLATED GLP-1 DERIVATIVES

The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 37 of GLP-1 (7-37) (SEQ ID NO: 1), a second K residue at a position corresponding to position 26 of GLP-1 (7-37), and a maximum of ten amino acid modifications as compared to GLP-1 (7-37), wherein the first K residue is designated K37, and the second K residue is designated K26, which derivative comprises two albumin binding moieties attached to K26 and K37, respectively, wherein the albumin binding moiety comprises a protracting moiety selected from: ????????Chem. 1:?????HOOC-(CH2)x-CO-* ????????Chem. 2:?????HOOC-C6H4-O-(CH2)y-CO-* ????????Chem. 3:?????R1-C6H4-(CH2)z-CO-* ????????Chem. 4:?????HOOC-C4SH2-(CH2)w-CO-* in which x is an integer in the range of 6-18, y is an integer in the range of 3-17, z is an integer in the range of 1-5, R1 is a group having a molar mass not higher than 150 Da, and w is an integer in the range of 6-18; with the proviso that when the protracting moiety is Chem. 1, the albumin binding moiety further comprises a linker of formula Chem. 5: *-NH-(CH2)2-(O-(CH2)2)k-O-(CH2)n-CO-*, wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel peptides and side chain intermediates. The derivatives are suitable for oral administration.

RADIOACTIVE HALOGEN LABELED COMPOUNDS OR SALTS THEREOF, AND PHARMACEUTICALS CONTAINING THE SAME

PROBLEM TO BE SOLVED: To provide radioactive halogen labeled compounds which have high selectivity for CYP11B2 over CYP11B1 and accumulation selectivity in the adrenal gland compared to the surrounding organs. SOLUTION: The present invention provides radi